MCL1 and acute myeloid leukemia: VTX (a selective BCL-2 inhibitor) plus AZA (a hypomethylating agent that also suppresses anti-apoptotic proteins like MCL-1) [37, 38], has become the standard of care for newly diagnosed AML patients, unfitted for intensive chemotherapy [39].